🔔Stock Alerts via Telegram — Free for All Users

OMDA Stock Risk & Deep Value Analysis

Omada Health Inc

DVR Score

6.5

out of 10

Solid Pick

What You Need to Know About OMDA Stock

We analyzed Omada Health Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran OMDA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated May 4, 2026Run Fresh Analysis →

OMDA Risk Analysis & Red Flags

What Could Go Wrong

Omada's profitability could prove inconsistent, especially if growth slows or competitive pressures intensify, leading to sustained operational losses. This might necessitate further capital raises, diluting existing shareholders and severely hindering the path to 10x growth potential.

Risk Matrix

Overall

Aggressive

Financial

Medium

Market

Medium

Competitive

High

Execution

Medium

Regulatory

Medium

Red Flags

  • CEO Sean P. Duffy and other insiders sold shares totaling $120,483 in the last 90 days, despite recent profitability.

  • Q1 2026 consensus EPS estimate is negative (-$0.13), following a profitable Q4 2025, suggesting inconsistent profitability.

  • Significant competition from larger players like Hinge Health (guiding much higher revenue) could cap Omada's market share expansion.

Upcoming Risk Events

  • 📅

    Disappointing Q1 2026 earnings or negative guidance

  • 📅

    Increased competitive pressure impacting market share or pricing

When to Reconsider

  • 🚪

    Exit if quarterly revenue growth decelerates below 25% year-over-year for two consecutive quarters.

  • 🚪

    Sell if the company reports sustained net losses without a clear path to profitability or significant cash burn without sufficient cash reserves.

Unlock OMDA Risk Analysis & Red Flags

Create a free account to see the full analysis

Investment Thesis

Omada Health is a high-growth small-cap company positioned in the expanding digital chronic care management market, demonstrating a successful pivot to profitability and strong gross margins. Its scalable platform and positive institutional interest suggest significant upside potential as it captures market share and consolidates its competitive position, aiming for sustained long-term growth and potential 10x returns as a future market leader.

Is OMDA Stock Undervalued?

Score Change Explanation: The previous analysis on 2026-03-13 assigned a score of 0.1/10 (1/100) because Omada Health Inc. was identified as a privately held company, making an analysis based on public stock metrics invalid. The current analysis, dated 2026-05-04, is based on extensive real-time market intelligence that confirms Omada Health Inc. (OMDA) is now publicly traded. This fundamental change in the company's trading status necessitates a complete re-evaluation of its investment potential as a public stock. Omada Health (OMDA) shows promising 10x potential within 3-5 years, driven by its 58% YoY revenue growth and recent achievement of GAAP profitability (Q4 2025). Operating in the high-growth digital chronic care management market, its 72.6% gross margin is strong. Institutional interest is positive, with significant inflows. However, the path to sustained profitability is not yet fully established, indicated by a projected negative EPS for Q1 2026. Competitive intensity from larger players like Hinge Health and insider selling activity represent notable risks. While the company is making strong strides, a clear, expanding competitive moat needs further demonstration to solidify its long-term market leadership and justify maximal 10x confidence. Financial health details are also somewhat limited from the provided snapshot, necessitating a cautious but optimistic assessment.

Unlock the full AI analysis for OMDA

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

OMDA Price Targets & Strategy

12-Month Target

$29.00

Bull Case

$42.00

Bear Case

$16.00

Valuation Basis

Based on 3.5x P/S applied to estimated FY26 revenue of $479M, yielding $1.67B market cap, divided by estimated shares outstanding of 57.25M (current market cap / current price).

Entry Strategy

Dollar-cost average between $14.50-$16.50, buying on dips towards previous support levels around $14.

Exit Strategy

Take initial profits at $25-$28, with a stop loss at $13.50 if growth decelerates significantly.

Portfolio Allocation

5% for aggressive risk tolerance

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is OMDA Financially Healthy?

Valuation

P/E Ratio

-78.68

Profitability

Gross Margin

65.69%

Operating Margin

-5.41%

Net Margin

-4.91%

Return on Equity

-7.10%

EPS

$-0.23

Balance Sheet

Current Ratio

3.60

Quick Ratio

3.47

Other

Beta (Volatility)

2.36

Does OMDA Have a Competitive Moat?

Sign in to unlock

Moat Rating

🛡️ Narrow

Moat Trend

Expanding

Moat Sources

2 Identified

Switching Costs (patient engagement, data integration with health systems)Intangible Assets/IP (proprietary clinical protocols, data-driven insights)

The moat is strengthening as Omada accumulates patient data, refines its programs, and deepens integrations with partners, increasing the switching costs for users and clients. However, new entrants or competitive innovations could still pose threats without a unique technological or regulatory barrier.

Moat Erosion Risks

  • Competitors developing superior or more cost-effective digital health solutions.
  • Failure to achieve consistent, demonstrably better health outcomes for patients.
  • Rapid shifts in healthcare policy or employer benefit preferences.

OMDA Competitive Moat Analysis

Sign up to see competitive advantages

OMDA Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Neutral. Limited specific data available in the provided intelligence for strong social media sentiment trends.

Institutional Sentiment

Positive. 25 institutional buyers with $121.60M inflows and 0 sellers in the last 12 months, and 'Moderate Buy' analyst consensus.

Insider Activity (Form 4)

CEO Sean P. Duffy sold 4,063 shares ($58,263) on March 9, 2026. Total insiders sold 8,776 shares ($120,483) in last 90 days. No insider buys reported.

Options Flow

Normal options activity. No specific unusual options activity was reported in the provided intelligence.

Earnings Intelligence

Next Earnings

2026-05-07

Surprise Probability

Medium

Historical Earnings Pattern

Only one recent earnings report (Q4 2025) showing an EPS beat, making a definitive historical pattern difficult to establish. The stock reaction to the Q1 2026 report will be key.

Key Metrics to Watch

Revenue growth rate (YoY)Profitability trajectory (EPS and net income)Gross margin trendsForward guidance for Q2 2026 and full year

Competitive Position

Top Competitor

Hinge Health (HNGE)

Market Share Trend

Gaining. Demonstrated by 58% YoY revenue growth, outpacing some competitors in percentage terms.

Valuation vs Peers

Trading broadly in line or slightly higher P/S (approx. 3x annualized Q4 revenue) compared to peers like Hims & Hers (HIMS, ~1.9x) and Hinge Health (HNGE, ~2.7x), considering its smaller size and higher recent growth rate.

Competitive Advantages

  • Strong gross margins (72.6%) indicating efficient service delivery.
  • Proven platform for chronic disease management achieving GAAP profitability.
  • Established partnerships within employer and health plan ecosystems.

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive OMDA Stock Higher?

Near-Term (0-6 months)

  • Q1 2026 Earnings on 2026-05-07 (after market close)
  • Potential announcements of new health plan or employer partnerships

Medium-Term (6-18 months)

  • Expansion into additional chronic disease areas or new geographic markets
  • Strategic integrations or product enhancements to improve patient outcomes and engagement

Long-Term (18+ months)

  • Emergence as a dominant, comprehensive digital health platform for chronic care
  • Further validation of cost savings and health outcome improvements leading to increased adoption

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for OMDA?

  • Acceleration in revenue growth above 60% YoY.

  • Consistent GAAP profitability and positive free cash flow generation.

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

How Omada Health Inc Makes Money

Omada Health provides a comprehensive digital platform designed to help individuals manage and prevent chronic conditions such as diabetes, hypertension, and behavioral health issues. The company partners primarily with large employers and health plans, offering personalized, evidence-based programs that combine digital tools, expert coaching, and peer support. Revenue is generated through these enterprise contracts, typically based on a per-member-per-month (PMPM) fee or value-based agreements tied to health outcomes, aiming to reduce long-term healthcare costs for its clients.

Read Full Business Model Breakdown

FAQ

What is the DVR Score for Omada Health Inc (OMDA)?

As of May 4, 2026, Omada Health Inc has a DVR Score of 6.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Omada Health Inc?

Omada Health Inc's market capitalization is approximately $901.0M..

What is the risk level for OMDA stock?

Our analysis rates Omada Health Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of OMDA?

Omada Health Inc currently has a price-to-earnings (P/E) ratio of -78.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.

Is OMDA stock profitable?

Omada Health Inc has a profit margin of -4.9%. The company is currently unprofitable.

How often is the OMDA DVR analysis updated?

Our AI-powered analysis of Omada Health Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 4, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for OMDA (Omada Health Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.

Navigated to OMDA Stock Risk & Deep Value Analysis